Source: Annual Congress 2008 - Multidrug-resistant and the emerging threat of extensively drug-resistant tuberculosis
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
B. Eker, J. Ortmann, G. B. Migliori, R. Muetterlein, R. Centis, A. Esselmann, B. Kretz, T. Schaberg, C. Schaudt, H. Hang, S. Ott, D. Kirsten, P. Hammel, R. Eberhardt, M. Pletz, H. Flick, S. Ruesch-Gerdes, P. Hannemann, S. Stenger, A. Paulick, K. D. Schnei. MDR- and XDR-TB in Germany. Eur Respir J 2008; 32: Suppl. 52, 1355

Member's Comments

No comment yet.

Related content which might interest you: Who is responsible for MDR- TB? Source: International Congress 2015 – WHO guidelines in TB and clinical practice Year: 2015 Treatment options for MDR- and XDR-TB Source: Eur Respir Monogr 2017; 75: 232-244 Year: 2017 Risk of mortality of extensively drug-resistant tuberculosis (XDR-TB) in Italy and Germany Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis Year: 2007 XDR-TB and MDR-TB in Europe: still a challenge Source: Annual Congress 2011 - PG12 TB-PAN-NET Multidrug-resistant and extensively drug-resistant tuberculosis: update on clinical management Year: 2011 Multidrug-resistant tuberculosis (MDR-TB) Source: Breathe 2010; 6: 283 Year: 2010 Extensively drug-resistant tuberculosis (XDR-TB) and multidrug-resistant tuberculosis (MDR-TB): a retrospective comparative study Source: Annual Congress 2008 - Multidrug-resistant and the emerging threat of extensively drug-resistant tuberculosis Year: 2008 Linezolid in the treatment of patients with MDR TB and XDR TB Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Early access to bedaquiline for extensively drug-resistant (XDR) and pre-XDR tuberculosis Source: Eur Respir J, 54 (1) 1802208; 10.1183/13993003.02208-2018 Year: 2019 Why did they get XDR TB ? Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis Year: 2011 Multidrug-resistant tuberculosis (MDR-TB) and HIV co-infection in Romania Source: Annual Congress 2011 - Tuberculosis in immunocompromised hosts Year: 2011 Determinants of multidrug-resistant tuberculosis (MDR-TB) in Belarus Source: Annual Congress 2012 - MDR- and XDR-TB: epidemiological and public health overview Year: 2012 MDR-TB and XDR-TB: drug resistance and treatment outcomes Source: Eur Respir J 2009; 34: 778 Year: 2009 Treating extensively drug resistant tuberculosis (XDR-TB) in India Source: Annual Congress 2008 - Epidemiology and clinical management of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2008 Evaluation of failures treated with linezolid-containing regimen for extensively drug-resistant tuberculosis (XDR-TB) Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Trend in rifampicin-, multidrug- and extensively drug-resistant tuberculosis in Italy, 2009–2016 Source: Eur Respir J, 52 (1) 1800070; 10.1183/13993003.00070-2018 Year: 2018 Extensively drug-resistant (XDR) pulmonary tuberculosis in HIV negative cases Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008 Analysis of multidrug-resistant tuberculosis Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 1 Year: 2014 Treatment outcomes of extensively-drug resistant tuberculosis (XDR-TB) patients in 20 countries Source: Annual Congress 2012 - Pros and cons of MDR- and XDR-TB treatment Year: 2012 Prevalence of MDR TB and XDR TB in a tertiary care hospital in India Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis Year: 2008 Efficiency of Bedaquiline in treatment of XDR-TB Source: International Congress 2017 – TB: diagnosis, severity and practical management Year: 2017